Brent Pfeiffenberger bought $17k of IPSC
President and CEO at Century Therapeutics, Inc.. 35,000 shares at an average of $0.50, traded Nov 19, 2025, filed Nov 20, 2025.
Score components
- +25RoleCEO
- 0Trade size$17k at market
- 0Relative to holdingsHoldings up 1.1%
- +8Price context70% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001162-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | POpen-market purchase Common Stock | +35,000 | $0.50 | $17k | 3,271,453 | Nov 20, 2025 |
Related signals
Other insiders at Century Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Century Therapeutics, Inc. | Douglas Carr SVP Finance & Operations | $3,200 1,658 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Gregory Russotti See Remarks | $4,993 2,587 shares | -1% | |
| 23Weak | Century Therapeutics, Inc. | Douglas Carr SVP Finance & Operations | $521 254 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Gregory Russotti See Remarks | $1,095 534 shares | -0% | |
| 37Weak | Century Therapeutics, Inc. | Chad Cowan Chief Scientific Officer | $49k 58,060 shares | +6% | |
| 51Moderate | Century Therapeutics, Inc. | Brent Pfeiffenberger President and CEO | $30k 52,000 shares | +2% | |
| 23Weak | Century Therapeutics, Inc. | Douglas Carr SVP Finance & Operations | $137 257 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Gregory Russotti See Remarks | $280 526 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Chad Cowan Chief Scientific Officer | $2,736 5,462 shares | -1% | |
| 40Moderate | Century Therapeutics, Inc. | Brent Pfeiffenberger President and CEO | $15k 32,456 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.